BrightSpec

Do you know your structures? If not, BrightSpec’s MRR can provide the answer!
Win a prize by choosing the correct structure. Which of these molecules is the active form of Ibuprofen?
https://media-exp1.licdn.com/dms/image/C4D22AQEAnvgr7dLbRw/feedshare-shrink_1280-alternative/0?e=1608163200&v=beta&t=OSRd1xHkoqI07XebLY10WpcUeeMeQYGY7r1E-0jF6rY
Enter your answer to win…
https://lnkd.in/dsDqRc4


No alternative text description for this image

media-exp1.licdn.com

Congratulations to BrightSpec advisor Frank Gupton and team for receiving funding for this important project! BrightSpec looks forward to working with Phlow to make this happen.

Trump administration taps startup to build stockpile of key drug ingredients The $354 million project is designed to shore up the drug supply chain and reduce the country's dependence on foreign manufacturers.

Covid-19 will spur a renaissance in U.S. drug manufacturing.
This hydroxychloroquine shortage is one of several breakdowns related to overseas manufacture of our API's and drugs. The pharma industry has resisted adopting new technologies such as continuous manufacturing given the more proven regulatory pathway of batch manufacturing and the low cost sourcing options overseas. Leave it to a crisis for the government and industry to recognize the imperatives of domestic manufacture. Continuous manufacturing, enabled by technologies such as BrightSpec MRR which can monitor processes in real-time, will enable domestic drug manufacture at lower cost, faster scale-up of production, and a higher quality and hence safer product. I'm looking forward to help make this a reality.
https://lnkd.in/eYhDxDw hashtag hashtag hashtag hashtag hashtag hashtag
In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won't hit its pledge after the government of Finland effectively turned off the tap for necessary ingredien...

FIERCEPHARMA.COM
Amneal faces hydroxychloroquine API shortage after Finland tightens production: report
In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won't hit its pledge after the government of Finland effectively turned off the tap for necessary ingredien...

Amneal faces hydroxychloroquine API shortage after Finland tightens production: report In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won't hit its pledge after the government of Finland effectively turned off the tap for necessary ingredien...